CD19 and cancer: Pseudoprogression is also observed in patients treated with CD19 specific chimeric antigen receptor T cell (CAR-T) therapy, which is also a new promising cancer immunotherapy that is now approved for the treatment of relapsed/refractory diffuse B cell lymphoma [59].